A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing ...

The FDA has approved bevacizumab-nwgd, a biosimilar to bevacizumab, for intravenous use across multiple cancer types.

The FDA has fully approved larotrectinib for adult and pediatric patients with solid tumors that harbor an NTRK gene fusion.

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

Addressing issues such as congestive heart failure is important to providing safe care to patients with cancer.

Marc Raab, MD, PhD, discussed the MajesTEC-5 trial of teclistamab plus standard myeloma therapies in transplant-eligible newly diagnosed multiple myeloma.

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

A phase 1b trial is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell ...

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

John L. Marshall, MD, discusses the sequencing of targeted therapy for refractory metastatic colorectal cancer.

The FDA has granted 501(k) clearance to ZEISS INTRABEAM 700, a robotic-assisted platform designed to enhance intraoperative ...

A retrospective study showed that either folate receptor alpha or B7-H4 was expressed in more than 80% of endometrial cancers ...